Leverage, a defining feature of many semiliquid strategies, is paramount among those risks. By borrowing money to buy more ...
MedPage Today on MSN
Double-Action Lupus Drug Looks Good in Phase III Trial
A novel drug for systemic lupus erythematosus (SLE) first developed in China, and approved there since 2021, did well enough in a new placebo-controlled phase III trial that approval in Western ...
Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback